Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 52,381 shares, an increase of 30.1% from the December 15th total of 40,257 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 171,579 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 171,579 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are short sold.
Rafael Trading Up 0.8%
NYSE:RFL traded up $0.01 during midday trading on Friday, hitting $1.25. 41,107 shares of the company were exchanged, compared to its average volume of 120,066. Rafael has a fifty-two week low of $1.12 and a fifty-two week high of $3.19. The company has a market capitalization of $64.71 million, a PE ratio of -1.47 and a beta of 0.67. The company has a fifty day simple moving average of $1.26 and a 200 day simple moving average of $1.47.
Rafael (NYSE:RFL – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.28) earnings per share (EPS) for the quarter. Rafael had a negative net margin of 3,044.70% and a negative return on equity of 32.82%. The company had revenue of $0.89 million during the quarter.
Institutional Investors Weigh In On Rafael
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rafael in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.
View Our Latest Research Report on Rafael
Rafael Company Profile
Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
See Also
- Five stocks we like better than Rafael
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Trump Planning to Use Public Law 63-43: Prepare Now
- Your “birthright claim” just got activated
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
